Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Yellow fever disease in a renal transplant recipient: Case report and literature review.

de Sousa MV, Zollner RL, Stucchi RSB, Boin IFSF, de Ataide EC, Mazzali M.

Transpl Infect Dis. 2019 Jul 25:e13151. doi: 10.1111/tid.13151. [Epub ahead of print]

PMID:
31344763
2.

Pregnancy Among Women with Kidney Transplantation: A 20-Years Single-Center Registry.

Mariano S, Guida JPS, Sousa MV, Parpinelli MA, Surita FG, Mazzali M, Costa ML.

Rev Bras Ginecol Obstet. 2019 Jul;41(7):419-424. doi: 10.1055/s-0039-1688834. Epub 2019 Jun 27.

3.

Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation.

Tedesco-Silva H, Del Carmen Rial M, Cruz Santiago J, Mazzali M, Pacheco-Silva A, Torres R.

Clin Transplant. 2019 Feb;33(2):e13464. doi: 10.1111/ctr.13464. Epub 2019 Jan 2. Review.

PMID:
30548896
4.

Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients.

de Sousa MV, Gonçalez AC, Zollner RL, Mazzali M.

Ann Transplant. 2018 Jul 6;23:457-466. doi: 10.12659/AOT.908491.

5.

Polyomavirus infection: can early diagnosis prevent development of associated allograft nephropathy?

Mazzali M.

J Bras Nefrol. 2018 Jan-Mar;40(1):8-9. doi: 10.1590/1678-4685-JBN-3986. Epub 2018 Apr 9. English, Portuguese. No abstract available.

6.

Effects of a Physiotherapeutic Protocol in Respiratory Function, Aerobic Capacity and Quality of Life After Kidney Transplantation.

Campanati-Palhares L, Simoncini TC, da Silva Augusto PG, Masi Galhardo FD, Pereira MG, Vian BS, Mazzali M.

Transplant Proc. 2018 Apr;50(3):750-753. doi: 10.1016/j.transproceed.2018.02.045.

PMID:
29661429
7.

Immunization in end stage renal disease: The perception of waiting list patients.

Camargo LF, Lother AM, Mazzali M, Stucchi RSB.

Transpl Infect Dis. 2018 Jun;20(3):e12831. doi: 10.1111/tid.12831. Epub 2018 Feb 12.

PMID:
29337400
8.

Early Vascular Thrombosis After Kidney Transplantation: Can We Predict Patients at Risk?

de Freitas RAP, de Lima ML, Mazzali M.

Transplant Proc. 2017 May;49(4):817-820. doi: 10.1016/j.transproceed.2017.03.004.

PMID:
28457402
9.

Spironolactone in Post-Transplant Proteinuria: A Safe Alternative Therapy.

de Sousa MV, Guida JP, do Valle CF, Camargo LF, Rivelli GG, Mazzali M.

Transplant Proc. 2017 May;49(4):813-816. doi: 10.1016/j.transproceed.2017.01.075.

PMID:
28457401
10.

Evaluation of tolerability of enteric-coated mycophenolate sodium versus mycophenolate mofetil in de novo renal transplantation.

Pacheco e Silva Filho A, Manfro RC, Contieri FL, Mazzali M, Garcia VD, Carvalho Dde B, David S, Machado P, Rodrigues CA.

J Bras Nefrol. 2015 Jul-Sep;37(3):291-6. doi: 10.5935/0101-2800.20150048. English, Portuguese.

11.

Urinary tract infection in renal transplant recipients: incidence, risk factors, and impact on graft function.

Camargo LF, Esteves AB, Ulisses LR, Rivelli GG, Mazzali M.

Transplant Proc. 2014 Jul-Aug;46(6):1757-9. doi: 10.1016/j.transproceed.2014.05.006.

PMID:
25131029
12.

C4d deposits in borderline rejection: an early marker for chronic renal dysfunction?

Sampaio WL, Mazzali M.

Transplant Proc. 2014 Jul-Aug;46(6):1710-2. doi: 10.1016/j.transproceed.2014.05.014.

PMID:
25131018
13.

Bladder function evaluation before renal transplantation in nonurologic disease: is it necessary?

Silva DM, Prudente AC, Mazzali M, Borges CF, D'Ancona C.

Urology. 2014 Feb;83(2):406-10. doi: 10.1016/j.urology.2013.09.015. Epub 2013 Nov 6.

PMID:
24210566
14.

What are the key arguments against uric acid as a true risk factor for hypertension?

Johnson RJ, Sánchez-Lozada LG, Mazzali M, Feig DI, Kanbay M, Sautin YY.

Hypertension. 2013 May;61(5):948-51. doi: 10.1161/HYPERTENSIONAHA.111.00650. Epub 2013 Mar 4. No abstract available.

PMID:
23460277
15.

Can pre-liver transplantation renal insufficiency using a creatinine clearance calculator predict long-term survival?

Boin IF, de Ataide EC, Dias EP, Stucchi RS, Seva-Pereira T, Calomeni G, Capel Junior CC, Mazzali M.

Transplant Proc. 2012 Oct;44(8):2452-4. doi: 10.1016/j.transproceed.2012.07.028.

16.

Prevalence of urinary decoy cells and associated risk factors in a Brazilian kidney, pancreas, and kidney-pancreas transplant population.

Kroth LV, Henkin CS, Peres LD, Paganella MC, Mazzali M, Duval VD, Traesel MA, Saitovitch D.

Transplant Proc. 2012 Oct;44(8):2394-6. doi: 10.1016/j.transproceed.2012.07.008.

PMID:
23026603
17.

Nutritional status and body composition in patients early after renal transplantation.

Netto MC, Alves-Filho G, Mazzali M.

Transplant Proc. 2012 Oct;44(8):2366-8. doi: 10.1016/j.transproceed.2012.07.041.

PMID:
23026594
18.

Sirolimus in renal transplantation: analysis of safety and efficacy in a nonprotocol conversion group.

Gois PH, Rivelli GG, Pereira LM, Mazzali M.

Transplant Proc. 2012 Oct;44(8):2348-51. doi: 10.1016/j.transproceed.2012.07.010.

PMID:
23026590
19.

Guidelines for maintenance of adult patients with brain death and potential for multiple organ donations: the Task Force of the Brazilian Association of Intensive Medicine the Brazilian Association of Organs Transplantation, and the Transplantation Center of Santa Catarina.

Westphal GA, Caldeira Filho M, Fiorelli A, Vieira KD, Zaclikevis V, Bartz M, Wanzuita R, Teixeira C, Franke C, Machado FO, Friedman G, Andrade J, Matos JD, Lamgaro DM, Silva E, Costa G, Coelho ME, Oliveira MC, Youssef NC, Akamine N, Duarte P, Lisboa R, Mazzali M, Ferraz Neto BH; Task Force of the Brazilian Association of Intensive Medicine, Brazilian Association of Organs Transplantation, Transplantation Center of Santa Catarina.

Transplant Proc. 2012 Oct;44(8):2260-7. doi: 10.1016/j.transproceed.2012.07.019. Review.

PMID:
23026569
20.
21.

Use of uric acid-lowering agents limits experimental cyclosporine nephropathy.

Mazali FC, Johnson RJ, Mazzali M.

Nephron Exp Nephrol. 2012;120(1):e12-9. doi: 10.1159/000330274. Epub 2011 Nov 25.

22.

Guidelines for potential multiple organ donors (adult). Part III: organ-specific recommendations.

Westphal GA, Caldeira Filho M, Vieira KD, Zaclikevis VR, Bartz MC, Wanzuita R, Réa-Neto A, Teixeira C, Franke C, Machado FO, Andrade Jd, Matos JD, Gerent KB, Fiorelli A, Gonçalves AR, Ferraz Neto BH, Dias FS, Carvalho FB, Costa G, Camargo JJ, Teles JM, Maia M, Nogara M, Coelho ME, Mazzali M, Youssef NC, Duarte P, Souza RL, Fernandes R, Camargo S, Garcia VD.

Rev Bras Ter Intensiva. 2011 Dec;23(4):410-25. English, Portuguese.

PMID:
23949454
23.

Uric acid and transplantation.

Mazali FC, Mazzali M.

Semin Nephrol. 2011 Sep;31(5):466-71. doi: 10.1016/j.semnephrol.2011.08.012.

PMID:
22000655
24.

Uric acid and hypertension: cause or effect?

Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, Johnson RJ.

Curr Rheumatol Rep. 2010 Apr;12(2):108-17. doi: 10.1007/s11926-010-0094-1. Review.

PMID:
20425019
25.

Kidney transplant anastomosis: internal or external iliac artery?

Matheus WE, Reis LO, Ferreira U, Mazzali M, Denardi F, Leitao VA, Pedro RN, Netto NR Jr.

Urol J. 2009 Fall;6(4):260-6.

26.

Tuberculosis in renal transplant recipients: a Brazilian center registry.

Guida JP, Bignotto Rosane D, Urbini-Santos C, Alves-Filho G, Ribeiro Resende M, Mazzali M.

Transplant Proc. 2009 Apr;41(3):883-4. doi: 10.1016/j.transproceed.2009.01.075.

PMID:
19376379
27.

Delayed graft function in renal transplant recipients: risk factors and impact on 1-year graft function: a single center analysis.

Bronzatto EJ, da Silva Quadros KR, Santos RL, Alves-Filho G, Mazzali M.

Transplant Proc. 2009 Apr;41(3):849-51. doi: 10.1016/j.transproceed.2009.02.004.

PMID:
19376369
28.

Administration of neural precursor cells ameliorates renal ischemia-reperfusion injury.

Wang PH, Schwindt TT, Barnabé GF, Motta FL, Semedo P, Beraldo FC, Mazzali M, Dos Reis MA, Teixeira Vde P, Pacheco-Silva A, Mello LE, Câmara NO.

Nephron Exp Nephrol. 2009;112(1):e20-8. doi: 10.1159/000210575. Epub 2009 Apr 3.

29.

Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis.

Feitoza CQ, Gonçalves GM, Semedo P, Cenedeze MA, Pinheiro HS, Beraldo FC, dos Santos OF, Teixeira Vde P, dos Reis MA, Mazzali M, Pacheco-Silva A, Câmara NO.

Mol Med. 2008 Nov-Dec;14(11-12):724-30. doi: 10.2119/2008-00064.Feitoza. Epub 2008 Aug 18.

30.

A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury.

Fernandes Bertocchi AP, Campanhole G, Wang PH, Gonçalves GM, Damião MJ, Cenedeze MA, Beraldo FC, de Paula Antunes Teixeira V, Dos Reis MA, Mazzali M, Pacheco-Silva A, Câmara NO.

Transpl Int. 2008 Oct;21(10):999-1007. doi: 10.1111/j.1432-2277.2008.00705.x. Epub 2008 Jul 24.

31.

Improved renal function after kidney transplantation is associated with heme oxygenase-1 polymorphism.

Ozaki KS, Marques GM, Nogueira E, Feitoza RQ, Cenedeze MA, Franco MF, Mazzali M, Soares MP, Pacheco-Silva A, Câmara NO.

Clin Transplant. 2008 Sep-Oct;22(5):609-16. doi: 10.1111/j.1399-0012.2008.00832.x. Epub 2008 May 4.

PMID:
18459998
32.

Skin malignancies in renal transplant recipients: a Brazilian center registry.

Falsarella PM, Alves-Filho G, Mazzali M.

Transplant Proc. 2008 Apr;40(3):767-8. doi: 10.1016/j.transproceed.2008.02.046.

PMID:
18455011
33.

Posttransplant diabetes mellitus: incidence and risk factors.

Mazali FC, Lalli CA, Alves-Filho G, Mazzali M.

Transplant Proc. 2008 Apr;40(3):764-6. doi: 10.1016/j.transproceed.2008.03.018.

PMID:
18455010
34.

Changes in serological markers of hepatitis B virus after renal transplantation.

Urbini Dos Santos C, Sevá-Pereira T, Alves-Filho G, Lorena SL, Soares EC, Mazzali M.

Transplant Proc. 2008 Apr;40(3):749-51. doi: 10.1016/j.transproceed.2008.02.066.

PMID:
18455006
35.

Systemic lupus erythematosus after renal transplantation: is complement a good marker for graft survival?

Signori Baracat AL, Ribeiro-Alves MA, Alves-Filho G, Mazzali M.

Transplant Proc. 2008 Apr;40(3):746-8. doi: 10.1016/j.transproceed.2008.02.045.

PMID:
18455005
36.

The effects of rapamycin in the progression of renal fibrosis.

Damião MJ, Bertocchi AP, Monteiro RM, Gonçalves GM, Cenedeze MA, Feitoza CQ, Marques GD, Giannocco G, Mazzali M, Teixeira VP, Dos Reis MA, Pacheco-Silva A, Câmara NO.

Transplant Proc. 2007 Mar;39(2):457-9.

PMID:
17362758
37.

Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients.

Lieber SR, Perez FV, Tabossi MR, Persoli LB, Marques SB, Mazzali M, Alves-Filho G, de Souza CA.

Transplant Proc. 2007 Mar;39(2):429-31.

PMID:
17362748
38.
39.

Uric acid and hypertension.

Feig DI, Kang DH, Nakagawa T, Mazzali M, Johnson RJ.

Curr Hypertens Rep. 2006 May;8(2):111-5. Review.

PMID:
16672142
40.

Serum uric acid: a risk factor and a target for treatment?

Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ.

J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S69-73. Review.

41.

Nosocomial infections in renal transplant patients: risk factors and treatment implications associated with urinary tract and surgical site infections.

Dantas SR, Kuboyama RH, Mazzali M, Moretti ML.

J Hosp Infect. 2006 Jun;63(2):117-23. Epub 2006 Mar 3.

PMID:
16517007
42.

Uric acid--a uremic toxin?

Nakagawa T, Mazzali M, Kang DH, Sánchez-Lozada LG, Herrera-Acosta J, Johnson RJ.

Blood Purif. 2006;24(1):67-70. Review.

43.

The accuracy of (99m)Tc-DTPA scintigraphy in the evaluation of acute renal graft complications.

Sanches A, Etchebehere EC, Mazzali M, Filho GA, Lima MC, Santos AO, Ramos CD, Cardinalli I, Billis A, Camargo EE.

Int Braz J Urol. 2003 Nov-Dec;29(6):507-16.

44.

Uric acid and transplantation.

Mazzali M.

Semin Nephrol. 2005 Jan;25(1):50-5. Review.

PMID:
15660335
45.

[Quality of life in renal transplant patients: impact of a functioning graft].

Bittencourt ZZ, Alves Filho G, Mazzali M, Santos NR.

Rev Saude Publica. 2004 Oct;38(5):732-4. Epub 2004 Oct 18. Portuguese.

46.

Urine cytology as a screening method for polyoma virus active infection.

Santos RL, Manfrinatto JA, Cia EM, Carvalho RB, Quadros KR, Alves-Filho G, Mazzali M.

Transplant Proc. 2004 May;36(4):899-901.

PMID:
15194309
47.

Chronic liver disease in kidney recipients with hepatitis C virus infection.

Giordano HM, França AV, Meirelles L, Escanhoela CA, Nishimura NF, Santos RL, Quadros KR, Mazzali M, Alves-Filho G, Soares EC.

Clin Transplant. 2003 Jun;17(3):195-9.

PMID:
12780667
48.

Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension.

Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ.

Kidney Int. 2003 Jun;63(6):2088-93.

49.

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M.

Hypertension. 2003 Jun;41(6):1183-90. Epub 2003 Apr 21. Review.

PMID:
12707287
50.

Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules.

Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J.

J Am Soc Nephrol. 2003 Jan;14(1):139-47.

Supplemental Content

Loading ...
Support Center